Search results
Research Associate I - Noble/Jiang Lab - Lung Institute - Los Angeles, California job with...
Nature· 4 days agoAre you ready to be a part of breakthrough research? Cedars-Sinai offers scientists unparalleled access to ground breaking technologies, facilities, and resources for conducting ...
Breast cancer drug denied on NHS gives incurable women 'precious extra time'
Daily Express· 4 days agoA wonder drug denied to thousands of women in England with incurable breast cancer could keep their...
Weight loss jabs have 'enormous potential' to cut risk of obesity-related cancer
Daily Express· 3 days agoWeight loss jabs such as Ozempic have “enormous potential” as a new weapon in the fight against ...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 6 days agoInnovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting PR Newswire SAN FRANCISCO and SUZHOU, China, June 2, 2024 SAN FRANCISCO and
Moderna, Merck say vaccine improved survival in patients with deadly skin cancer
CNBC· 5 days agoModerna and Merck released more positive three-year data Monday on their experimental vaccine, given...
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R)...
Digital Journal· 5 days agoAt a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis ...
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1...
Morningstar· 7 days agoNuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO ...
Live from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in...
Benzinga· 6 days agoSUZHOU, China, and ROCKVILLE, Md., June 1, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related
Moderna, Merck say vaccine improved survival in patients with deadly skin cancer
NBC New York· 5 days agoModerna and Merck said their experimental vaccine in combination with the therapy Keytruda improved survival and showed durable efficacy in a midstage study in patients with a deadly form of ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 7 days agoPatients had received a median of three prior systemic anti-cancer regimens, including prior platinum-based chemotherapy, prior anti-PD1/L1 therapy, and prior epidermal growth ...
